C 반응성 단백질 검사 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of C-reactive protein (CRP) testing Market

The global C-reactive protein (CRP) testing market is projected to witness steady growth due to the rising prevalence of chronic diseases, increasing adoption of point-of-care (POC) testing, and growing awareness about the role of CRP as an inflammation marker. According to Fortune Business Insights, the market was valued at USD 2.55 billion in 2025, expected to grow to USD 2.69 billion in 2026, and is forecasted to reach USD 3.95 billion by 2034, registering a CAGR of 4.9% during the forecast period. North America dominated the market in 2025 with a share of 34.5%, driven by high disease burden, advanced healthcare infrastructure, and growing preference for CRP point-of-care tests.

CRP is a non-specific marker of inflammation and plays a critical role in predicting cardiovascular risks, including heart attack and stroke. It is also used in diagnosing chronic conditions such as cancer, rheumatoid arthritis, and other autoimmune diseases. The market growth is further supported by technological advancements in CRP testing instruments and kits, including POC solutions.

Market Dynamics

Drivers

The increasing prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders, has driven the demand for CRP testing. According to CDC data from 2022, approximately 20.1 million adults in the U.S. suffer from coronary artery disease, with an estimated 805,000 heart attacks occurring annually. The rising patient population and growing focus on preventive healthcare have fueled the adoption of CRP testing globally.

Another major driver is the development of point-of-care CRP tests, which aid clinicians in reducing antibiotic prescriptions and improving diagnostic efficiency. For instance, research published in the British Journal of General Practice (2022) highlighted the use of CRP POC testing for acute respiratory infections to minimize unnecessary antibiotic use. Companies such as Bloom Diagnostics and LumiraDx are launching advanced POC CRP tests to address this growing need.

Trends

The market is witnessing a growing focus on technologically advanced testing kits and instruments. The immunoturbidimetric assay segment dominated the market in 2026 with a 75.09% share, due to widespread product availability and strong adoption in clinical laboratories. High-sensitivity CRP (hs-CRP) testing is gaining traction for cardiovascular risk assessment. Additionally, the increasing use of POC tests in community healthcare settings is expected to drive growth further.

Restraints

CRP is a non-specific inflammation marker, which limits its use as a standalone diagnostic test. Alternative diagnostics, such as coronary CT angiography, electrocardiography (ECG), and stress tests, provide more accurate disease-specific results. The availability of these alternatives may slow the adoption of CRP tests to some extent.

Market Segmentation

By Product: The market is divided into reagents & kits and instruments. Reagents & kits dominated with a 73.61% share in 2026, driven by high testing volumes and strong offerings from key players like Abbott and LumiraDx. The instruments segment is expected to grow due to increasing regulatory approvals for innovative devices, such as the ProciseDx instrument approved by the U.S. FDA in 2022.

By Assay Type: The market is segmented into immunoturbidimetric assay, ELISA, CLIA, and others. Immunoturbidimetric assays lead due to ease of use and widespread adoption, while ELISA and CLIA-based assays are steadily growing, particularly for chronic disease detection.

By Detection Range: Conventional CRP dominated with an 89.96% share in 2026, primarily for chronic and autoimmune disease monitoring. High-sensitivity CRP tests are increasingly used for cardiovascular risk assessment.

By Setting: Laboratory testing led with 75.84% share in 2026, attributed to precise and comprehensive analysis. POC testing is expected to grow significantly in resource-limited or primary care settings.

By End-User: Diagnostic laboratories dominate due to the increasing number of tests for chronic disease management, while hospitals and clinics are expected to witness strong growth due to rising hospitalizations and clinical demand.

Regional Insights

• North America: USD 0.88B (2025), USD 0.85B (2026); dominated by U.S. chronic disease burden, innovation, and clinical research.
• Europe: UK USD 0.12B, Germany USD 0.18B (2026); growth supported by regulatory approvals, CE-marked products, and rising adoption for autoimmune disease monitoring.
• Asia Pacific: Japan USD 0.15B, China USD 0.22B, India USD 0.11B (2026); driven by chronic disease prevalence, public health initiatives, and strategic partnerships such as FIND-SD Biosensor collaborations.
• Latin America & Middle East/Africa: Moderate growth due to improving healthcare infrastructure and adoption of rapid diagnostic tests.

Key Industry Players

Prominent companies in the market include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Quest Diagnostics, Thermo Fisher Scientific, Merck KGaA, Getein Biotech, Randox Laboratories, Boditech Med, and LumiraDx. Market players are focusing on research and development, new product launches, and expanding POC offerings. For instance, Abbott's acquisition of Alere Inc. in 2016 expanded its POC testing portfolio.

Notable developments include Siemens FDA clearance for CardioPhase hs-CRP test (Dec 2022) and Boditech Med MoU for North American market entry (Mar 2022).

Conclusion

The global C-reactive protein testing market is projected to grow from USD 2.55 billion in 2025 to USD 3.95 billion by 2034, supported by rising chronic disease prevalence, increasing adoption of POC tests, and continuous innovation in assay technologies. Despite limitations due to alternative diagnostics, CRP testing remains a vital tool for inflammation monitoring, cardiovascular risk prediction, and improving patient management worldwide.

Segmentation By Product, Assay Type, Detection Range, Setting, End User, and Region

By Product * Reagents & Kits

• Instruments

By Assay Type * Chemiluminescence Immunoassay (CLIA)

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunoturbidimetric Assay
• Others

By Detection Range * Conventional CRP

• hs-CRP

By Setting

Laboratory Testing

• Point-of-Care (POC) Testing

By End User * Hospitals & Clinics

• Diagnostic Laboratories
• Others

By Region * North America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country)

• U.S.
• Canada
• Europe (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Chronic Diseases, By Key Countries/Regions
• 4.2. Technological Advancements in C-Reactive Protein Testing
• 4.3. New Product Launches
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Reagents & Kits
  • 5.1.2. Instruments
• 5.2. Market Analysis, Insights and Forecast - By Assay Type
  • 5.2.1. Chemiluminescence Immunoassay (CLIA)
  • 5.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 5.2.3. Immunoturbidimetric Assay
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Detection Range
  • 5.3.1. Conventional CRP
  • 5.3.2. Hs-CRP
• 5.4. Market Analysis, Insights and Forecast - By Setting
  • 5.4.1. Laboratory Testing
  • 5.4.2. Point-of-Care (POC) Testing
• 5.5. Market Analysis, Insights and Forecast - By End-User
  • 5.5.1. Hospitals & Clinics
  • 5.5.2. Diagnostic Laboratories
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Reagents & Kits
  • 6.1.2. Instruments
• 6.2. Market Analysis, Insights and Forecast - By Assay Type
  • 6.2.1. Chemiluminescence Immunoassay (CLIA)
  • 6.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 6.2.3. Immunoturbidimetric Assay
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Detection Range
  • 6.3.1. Conventional CRP
  • 6.3.2. Hs-CRP
• 6.4. Market Analysis, Insights and Forecast - By Setting
  • 6.4.1. Laboratory Testing
  • 6.4.2. Point-of-Care (POC) Testing
• 6.5. Market Analysis, Insights and Forecast - By End-User
  • 6.5.1. Hospitals & Clinics
  • 6.5.2. Diagnostic Laboratories
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Reagents & Kits
  • 7.1.2. Instruments
• 7.2. Market Analysis, Insights and Forecast - By Assay Type
  • 7.2.1. Chemiluminescence Immunoassay (CLIA)
  • 7.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 7.2.3. Immunoturbidimetric Assay
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Detection Range
  • 7.3.1. Conventional CRP
  • 7.3.2. Hs-CRP
• 7.4. Market Analysis, Insights and Forecast - By Setting
  • 7.4.1. Laboratory Testing
  • 7.4.2. Point-of-Care (POC) Testing
• 7.5. Market Analysis, Insights and Forecast - By End-User
  • 7.5.1. Hospitals & Clinics
  • 7.5.2. Diagnostic Laboratories
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Rest of Europe

8. Asia Pacific C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Reagents & Kits
  • 8.1.2. Instruments
• 8.2. Market Analysis, Insights and Forecast - By Assay Type
  • 8.2.1. Chemiluminescence Immunoassay (CLIA)
  • 8.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 8.2.3. Immunoturbidimetric Assay
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Detection Range
  • 8.3.1. Conventional CRP
  • 8.3.2. Hs-CRP
• 8.4. Market Analysis, Insights and Forecast - By Setting
  • 8.4.1. Laboratory Testing
  • 8.4.2. Point-of-Care (POC) Testing
• 8.5. Market Analysis, Insights and Forecast - By End-User
  • 8.5.1. Hospitals & Clinics
  • 8.5.2. Diagnostic Laboratories
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. Australia
  • 8.6.5. Rest of Asia Pacific

9. Latin America C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Reagents & Kits
  • 9.1.2. Instruments
• 9.2. Market Analysis, Insights and Forecast - By Assay Type
  • 9.2.1. Chemiluminescence Immunoassay (CLIA)
  • 9.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 9.2.3. Immunoturbidimetric Assay
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Detection Range
  • 9.3.1. Conventional CRP
  • 9.3.2. Hs-CRP
• 9.4. Market Analysis, Insights and Forecast - By Setting
  • 9.4.1. Laboratory Testing
  • 9.4.2. Point-of-Care (POC) Testing
• 9.5. Market Analysis, Insights and Forecast - By End-User
  • 9.5.1. Hospitals & Clinics
  • 9.5.2. Diagnostic Laboratories
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Reagents & Kits
  • 10.1.2. Instruments
• 10.2. Market Analysis, Insights and Forecast - By Assay Type
  • 10.2.1. Chemiluminescence Immunoassay (CLIA)
  • 10.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 10.2.3. Immunoturbidimetric Assay
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Detection Range
  • 10.3.1. Conventional CRP
  • 10.3.2. Hs-CRP
• 10.4. Market Analysis, Insights and Forecast - By Setting
  • 10.4.1. Laboratory Testing
  • 10.4.2. Point-of-Care (POC) Testing
• 10.5. Market Analysis, Insights and Forecast - By End-User
  • 10.5.1. Hospitals & Clinics
  • 10.5.2. Diagnostic Laboratories
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
  • 11.2.1. Abbott
    • 11.2.1.1. Overview,
    • 11.2.1.2. Product,
    • 11.2.1.3. SWOT Analysis,
    • 11.2.1.4. Recent Developments,
    • 11.2.1.5. Strategies,
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. F. Hoffmann-La Roche Ltd.
    • 11.2.2.1. Overview,
    • 11.2.2.2. Product,
    • 11.2.2.3. SWOT Analysis,
    • 11.2.2.4. Recent Developments,
    • 11.2.2.5. Strategies,
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Siemens Healthcare Private Limited
    • 11.2.3.1. Overview,
    • 11.2.3.2. Product,
    • 11.2.3.3. SWOT Analysis,
    • 11.2.3.4. Recent Developments,
    • 11.2.3.5. Strategies,
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Quest Diagnostics Incorporated
    • 11.2.4.1. Overview,
    • 11.2.4.2. Product,
    • 11.2.4.3. SWOT Analysis,
    • 11.2.4.4. Recent Developments,
    • 11.2.4.5. Strategies,
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Thermo Fisher Scientific, Inc.
    • 11.2.5.1. Overview,
    • 11.2.5.2. Product,
    • 11.2.5.3. SWOT Analysis,
    • 11.2.5.4. Recent Developments,
    • 11.2.5.5. Strategies,
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Merck KGaA
    • 11.2.6.1. Overview,
    • 11.2.6.2. Product,
    • 11.2.6.3. SWOT Analysis,
    • 11.2.6.4. Recent Developments,
    • 11.2.6.5. Strategies,
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Getein Biotech, Inc.
    • 11.2.7.1. Overview,
    • 11.2.7.2. Product,
    • 11.2.7.3. SWOT Analysis,
    • 11.2.7.4. Recent Developments,
    • 11.2.7.5. Strategies,
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Randox Laboratories Ltd.
    • 11.2.8.1. Overview,
    • 11.2.8.2. Product,
    • 11.2.8.3. SWOT Analysis,
    • 11.2.8.4. Recent Developments,
    • 11.2.8.5. Strategies,
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. BODITECH MED, INC.
    • 11.2.9.1. Overview,
    • 11.2.9.2. Product,
    • 11.2.9.3. SWOT Analysis,
    • 11.2.9.4. Recent Developments,
    • 11.2.9.5. Strategies,
    • 11.2.9.6. financials (Based on Availability)
  • 11.2.10. LumiraDx
    • 11.2.10.1. Overview,
    • 11.2.10.2. Product,
    • 11.2.10.3. SWOT Analysis,
    • 11.2.10.4. Recent Developments,
    • 11.2.10.5. Strategies,
    • 11.2.10.6. financials (Based on Availability)